[2026] NeuroFrontiers 2026 Participation | Exploring the Future of Neurodegenerative Disease Diagnostics in Singapore

Hello from Bredis Healthcare! On June 2, Bredis Healthcare attended NeuroFrontiers 2026: Biomarkers and Next-Generation Diagnostics in Neurological Disorders in Singapore. Hosted by A*STAR Singapore, this international workshop brought together leading experts, clinicians, scientists, and healthcare system leaders from Singapore, across Asia, and the United States to discuss the current landscape and future direction of biomarkers and next-generation diagnostic technologies for neurodegenerative diseases. The event provided valuable insights into the growing challenges posed by neurodegenerative disorders, including dementia, in rapidly aging societies across Asia. Participants explored how blood-based, imaging, and digital biomarkers, as well as multi-omics technologies, are advancing toward real-world clinical implementation. During the workshop, Bredis Healthcare introduced its neurology-focused biomarker analysis services powered by the ultra-sensitive SIMOA platform and the multiplex protein analysis technology NULISA. Through active networking sessions, we had the opportunity to engage with global researchers, clinicians, and industry experts while sharing our expertise in advanced biomarker analysis. It was a meaningful experience to witness firsthand how the diagnostic paradigm for neurodegenerative diseases is evolving across Asia as the region enters a super-aged society. Bredis Healthcare will continue to stay aligned with global research trends and contribute to the development of innovative diagnostic solutions for patients and healthcare providers worldwide. Thank you for your continued support.